Routine childhood immunizations

Primary Care - Clinics in Office Practice

Volumn 28, Issue 4, 2001, Pages 713-738

  Campbell, A L ^a   Bryant, K A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIAVAX II; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IPOL; M R VAX II; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MUMPS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; PNU IMMUNE 23; POLIOMYELITIS VACCINE; RUBELLA VACCINE; TETANUS TOXOID; TRIHIBIT; VACCINE;

ANAPHYLAXIS; BACTERIAL INFECTION; CHICKENPOX; CHILD CARE; CHILDHOOD MORTALITY; DIPHTHERIA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FEBRILE CONVULSION; FEVER; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INJECTION PAIN; MEASLES; MUMPS; NONHUMAN; PERTUSSIS; POLIOMYELITIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RUBELLA; TETANUS; THROMBOCYTOPENIA;

EID: 0035180621     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(05)70038-5     Document Type: Article

References (111)

1. Active and passive immunization
2. Tetanus
3. Measles
4. Measles immunization in HIV-infected children (RE9837)
5. Experience and reason: Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine
6. Hepatitis B vaccination and the risk of multiple sclerosis
7. Comparison of immunogenicity of two hepatitis A vaccines-VAQTA and HAVRIX-in young adults
8. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children
9. Epidemiology of hepatocellular carcinoma
10. Postnatal infectivity of hepatitis B surface antigen-carrier mothers
11. Thrombocytopenia after immunization with measles vaccines: Review of the Vaccine Adverse Events Reporting System (1990 to 1994)
12. Respiratory diphtheria in the United States, 1980-1995
13. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
14. Issues and challenges: Pneumococcal vaccination in pediatrics
15. Responses of infants to DTP-P vaccine in nine injection schedules
16. Serotype distribution of Streptococcus pneumoniae infection among preschool children in the United States, 1978-1994. Implication for development of conjugate vaccines
17. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination
18. Use of vaccines and immune globulins in persons with altered immunocompetence
19. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
20. Reported vaccine-preventable diseases - United States, 1993, and the Childhood Immunization Initiative
21. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
22. Update: Vaccine side effects, adverse reactions, contraindications, and precautions: Recommendation of the Advisory Committee on Immunization Practices (ACIP)
23. Measles, mumps, and rubella - Vaccine use and strategies for measles, rubella, and congenital rubella syndrome elimination and mumps control: Recommendations of the Immunization Practices Advisory Committee (ACIP)
24. Tetanus surveillance - United States, 1995-1997
25. Availability of a hepatitis B vaccine that does not contain thimerosol as a preservative
26. Epidemiology of measles - United States, 1998
27. Impact of vaccines universally recommended for children - United States, 1990-1998
28. Summary of notifiable diseases - United States, 1998
29. Notice to readers: Thimerosal in vaccines: A joint statement by the American Academy of Pediatrics and the Public Health Service
30. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
31. Update: Expanded availability of thimerosal preservative-free hepatitis B vaccine
32. Measles, rubella, and congenital rubella syndrome - United States and Mexico, 1997-1999
33. National, state, and urban vaccination coverage levels among children aged 19-35 months - United States, 1999
34. Poliomyelitis prevention in the United States
35. Preventing pneumococcal disease among infants and young children
36. Public health dispatch: Outbreak of poliomyelitis - Dominican Republic and Haiti
37. Recommended childhood immunization schedule - United States
38. Update: Vaccine side effects, adverse reactions, contraindications, and precautions. Recommendation of the Advisory Committee on Immunization Practices (ACIP)
39. Clinical experience with an inactivated hepatitis A vaccine
40. Immunization of U.S. children with H influenzae type b polysaccharide vaccine: A cost-effectiveness model of strategy assessment
41. Reduction of nasopharyngeal carriage during the second year of life by a heptavalent conjugate pneumococcal vaccine
42. Comparative trial in infants of 4 conjugate Haemophilus influenzae type b vaccines
43. Comparison of 13 acellular pertussis vaccines: Adverse reactions
44. Vaccination against Streptococcus pneumoniae in childhood: Lack of demonstrable benefit in young Australian children
45. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community
46. Comparison of 13 acellular pertussis vaccines: Overview and serologic response
47. Efficacy of pneumococcal conjugate vaccine against acute otitis media
48. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccine in childhood: Systemic and local immune responses
49. The epidemiology of mumps in southern Alberta, 1980-1982
50. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines
51. A case-control study of measles vaccination and inflammatory bowel disease
52. Measles-mumps vaccination in the FRG: An empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects
53. Varicella vaccine: Clinical trial in immunocompromised patients
54. Relapse in hepatitis A. Review of 14 cases and literature survey
55. A controlled trial of 2 acellular pertussis vaccines and one whole-cell vaccine against pertussis
56. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age
57. A controlled trial of a two-component acellular, five-component acellular, and a whole-cell pertussis vaccine
58. Absence of measles viral genomic sequence in intestinal tissues from Crohns disease by nested polymerase chain reaction
59. Live attenuated mumps virus vaccine
60. Safety and immunogenicity of hepatitis A vaccine in healthy children
61. Persistence of vaccine-induced immune responses to rubella: Comparison with natural infection
62. Chronic arthritis after rubella vaccination
63. Protection against hepatitis A by inactivated vaccine
64. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center
65. Adverse reactions to tetanus toxoid
66. A long-term prospective study of varicella vaccine in healthy children
67. Duration of immunity after rubella vaccination: A long term study in Switzerland
68. Oka/Merck varicelia vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow-up studies
69. Duration of live measles vaccine-induced immunity
70. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
71. Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults
72. Serologic response to oral polio vaccines and enhanced-potency inactivated polio vaccines
73. A search for Bordatella pertussis infection in university students
74. Humeral and mucosal immunity in infants induced by 3 sequential inactivated poliovirus vaccine-live attenuated poliovirus vaccine immunization schedules
75. Hepatitis B: Virology, epidemiology, disease and prevention, and an overview of viral hepatitis
76. VAQTA hepatitis: A vaccine, purified, inactivated
77. Neonatal deaths after hepatitis B vaccine
78. The measles epidemic: The problems, barriers, and recommendations
79. Risk of Guillain-Barreé syndrome after measles-mumps-rubella vaccination
80. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers
81. Risk of chronic arthropathy among women after rubella vaccination
82. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines
83. Bordatella pertussis infection: A cause of persistent cough in adults
84. Update on Haemophilus influenzae serotype b and meningococcal vaccines
85. School-based hepatitis B vaccination program and adolescent multiple sclerosis
86. Post-exposure varicella vaccination in siblings of children with active varicella
87. Clinical studies of pneumococcal vaccines in infants, I: Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines
88. Protective efficacy of varicella vaccine
89. Postexposure varicella vaccination in siblings of children with active varicella
90. Efficacy of acellular pertussis vaccine in early childhood after household exposure
91. The role of young children in a community wide outbreak of hepatitis A
92. Source of infection among persons with acute hepatitis A and no identified risk factors, Salt Lake County, Utah, 1997
93. Perinatal hepatitis B transmission in the United States: Prevention by passive-active immunization
94. Yeast-recombinant hepatitis B vaccine: Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission
95. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indiginous wild virus-associated disease
96. Postpartum rubella immunization: Association with development of prolonged arthritis, neurologic sequelae, and chronic rubella viremia
97. A placebo-controlled trial of a pertussis toxoid vaccine
98. Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus
99. Diphtheria in the former Soviet Union: Reemergence of a pandemic disease
100. Post-exposure effectiveness of varicella vaccine
101. Live attenuated varicella vaccine: Efficacy trial in healthy children
102. A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children
103. Health impact of varicella in the 1980's
104. Diphtheria and other diseases due to corynebacteria
105. Pertussis infection in adults with persistent cough
106. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: Preliminary report of a randomized, double-blind, placebo controlled and comparative trial
107. Association between administration of the hepatitis B Vaccine at birth and completion of the hepatitis B and 4:3:1: 3 Vaccine Series
108. No increase in demyelination diseases after hepatitis B vaccination